Sharer to step down as chairman and chief executive officer of Amgen
19 December 2011 | By Amgen
Kevin W. Sharer has announced his plan to retire from the Company at the end of 2012...
List view / Grid view
19 December 2011 | By Amgen
Kevin W. Sharer has announced his plan to retire from the Company at the end of 2012...
15 December 2011 | By Amgen
Additional key Nplate (Romiplostim) data also presented at American Society of Hematology annual meeting...
15 November 2011 | By Amgen
The EC has approved a variation to the marketing authorization for Vectibix®...
5 November 2011 | By Pfizer
PRESERVE trial results...
5 November 2011 | By Amgen
Positive data of the pivotal Phase 3 fracture trial...
19 October 2011 | By Amgen
Amgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...
13 October 2011 | By Amgen
Amgen announced that its Board of Directors has appointed Robert A. Bradway to the Company's Board...
22 August 2011 | By Amgen
The FDA will target a PDUFA action date of April 26, 2012 for the sBLA...
15 July 2011 | By Amgen
Amgen announced that the U.S. District Court in Pennsylvania has entered final judgment and a permanent injunction against TEVA...
15 July 2011 | By Amgen
The European Commission has granted marketing authorization for XGEVA® (denosumab)...
5 July 2011 | By Amgen
Amgen and UCB announced that they are collaborating with the NASA Ames Research Center to conduct a preclinical test...
27 June 2011 | By Amgen
Amgen announced the submission of a supplemental Biologics License Application to the U.S. FDA to expand the indication for XGEVA® (denosumab)...
20 May 2011 | By Amgen
Amgen announced that the CHMP of the EMA has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab)...
8 April 2011 | By Amgen
Amgen announced today the expansion of its operations in Brazil, including the acquisition of Bergamo...
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)...